Abstract:The detection of bisphosphonates is important due to the potential integrity and welfare issues associated with use of these substances. Targeted detection of a nitrogenous and non‐nitrogenous bisphosphonate was detected for 8 h and 28 days post‐administration, respectively. With this, the need for complementary indirect detection using lipid and corticosteroid biomarkers was investigated. Putative biomarkers were identified, which are now subject to validation into routine analysis for improved detection capabilities of bisphosphonate misuse in equine plasma. Detecting the use of bisphosphonates (BPs) in equine athletes is of interest to regulators and laboratories due to the threat to welfare issues for the potential to provide analgesic effects and manipulating bone structure. The detection of BPs in biological matrices is challenging due to erratic biological elimination and inconsistent analytical recoveries. Therefore, complementary approaches are needed to provide evidence of their misuse in racehorses. BPs have two sub‐classes: nitrogenous and non‐nitrogenous. This study investigated plasma elimination following administration of one example from each sub‐class, together with changes in endogenous eicosanoid and corticosteroids. Zoledronic acid (ZA) and tiludronic acid (TA) were administered by IV infusion to 8 thoroughbred horses with an 11‐month washout period between each administration. Sample preparation for quantification of BPs by liquid chromatography–tandem mass spectrometry (LC–MS/MS) utilised a two‐step solid phase extraction (SPE) consisting of polymeric reversed‐phase followed by weak anion exchange prior to derivatisation using trimethyl orthoacetate. Endogenous biomarkers were analysed after protein precipitation and SPE with polymeric reversed‐phase prior to liquid chromatography–high resolution mass spectrometry (LC‐HRMS) using data independent acquisition. The LC–MS/MS analysis showed ZA was undetectable after 8 h post‐administration while TA was detected up to the final collection point of 28 days post‐administration. The LC‐HRMS analysis utilised targeted (i.e., prior inclusion list of compounds) approaches to monitor level changes of eicosanoid and corticosteroid biomarkers. Putative biomarkers were identified and now subject to validation for translation into routine sample analysis for improved retrospectivity to detecting BP misuse in equine plasma.

Lipid and Corticosteroid Biomarkers Under the Influence of Bisphosphonates

Doping control analysis of myo‐inositol trispyrophosphate and 10 bisphosphonates in equine plasma by ion chromatography–mass spectrometry and its application to clodronic acid horse administration

Evaluating the Effects of Solid-Phase Cartridge Chemistry on Extraction of Bisphosphonates and ITPP From Equine Plasma

Detection of FG‐4592 and metabolites in equine plasma, urine and hair following oral administration

Label-free proteomics for discovering biomarker candidates of RAD140 administration to castrated horses

Rapid and sensitive determination of four bisphosphonates in rat plasma after MTBSTFA derivatization using liquid chromatography-mass spectrometry

Pharmacokinetic study of osilodrostat and identification of mono‐hydroxylated metabolite in equine plasma for the purpose of doping control

Discovery of Biomarkers of a Recombinant Human Erythropoietin Administration to Thoroughbred Geldings by Label-Free Proteomics

Detection of the selective androgen receptor modulator S-23 and its metabolites in equine urine and plasma following oral administration

A steroidomic approach for biomarkers discovery in doping control

Emerging Human Medications in Racing Animals: Analytical and Regulatory Challenges

Detection of nonsteroidal and steroidal selective androgen receptor modulators in equine hair after oral administrations

An enhanced label-free proteomics approach for deep-diving into equine plasma proteome, including the discovery of protein biomarkers for strenuous exercise

Detection of methandienone and its metabolites in equine urine, plasma and hair following a multidose oral administration

Detection of Over 110 Anabolic–Androgenic Steroids, Corticosteroids and/or Their Esters in Horse Hair Using Ultra‐High‐Performance Liquid Chromatography–High‐Resolution Mass Spectrometry and Gas Chromatography–Tandem Mass Spectrometry After Solid‐Supported Liquid Extraction

Development and validation of general plasma screening method for performance enhancing drugs in racehorses utilizing liquid chromatography-high-resolution mass spectrometry (LC-HRMS)

Quantification of glucocorticoid and progestogen metabolites in bovine plasma, skimmed milk and saliva by UHPLC-HR-MS with polarity switching

Non-Targeted Detection of Synthetic Oligonucleotides in Equine Serum Using Liquid Chromatography–High-Resolution Mass Spectrometry

Metabolic Pathway of Osilodrostat in Equine Urine Established through High-resolution Mass Spectrometric Characterization for Doping Control

Broad‐spectrum and sensitive screening of more than 1000 compounds in equine urine using liquid chromatography/high‐resolution mass spectrometry